All In Biotech

Drug Trial Radar · NCT04599972

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)

A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (the NEAR-2 Study: Near Eye-vision Acuity Restoration)

Last checked: Nov 19, 2026Latest source record: Apr 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 304 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

304

Actual

Start

Oct 26, 2020

Primary completion

Jan 21, 2022

Study completion Jan 28, 2022

Sponsor

Lead sponsor
Orasis Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Oct 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 4-visit, multi-center, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of CSF-1 in the temporary correction of presbyopia.

Conditions

  • Presbyopia

Interventions

  • CSF-1Drug

    One drop bilaterally twice daily for approximately 2 weeks.

  • VehicleDrug

    One drop bilaterally twice daily for approximately 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With a ≥ 3-line Gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8, 1 Hour Post-Dose 1.Time frame: Baseline (Day 1) to Day 8 (1 hour post-Dose 1)

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Orasis Investigative Site

    Chandler, Arizona

  • Orasis Investigative Site

    Mesa, Arizona

  • Orasis Investigative Site

    Phoenix, Arizona

  • Orasis Investigative Site

    Garden Grove, California

  • Orasis Investigative Site

    Mission Hills, California

  • Orasis Investigative Site

    Newport Beach, California

  • Orasis Investigative Site

    Petaluma, California

  • Orasis Investigative Site

    Littleton, Colorado

  • Orasis Investigative Site

    Danbury, Connecticut

  • Orasis Investigative Site

    Delray Beach, Florida

  • Orasis Investigative Site

    Rock Island, Illinois

  • Orasis Investigative Site

    Rochester, New York

  • Orasis Investigative Site

    Kingston, Pennsylvania

  • Orasis Investigative Site

    Cedar Park, Texas

  • Orasis Investigative Site

    San Antonio, Texas

  • Orasis Investigative Site

    Clinton, Utah

  • Orasis Investigative Site

    Draper, Utah

  • Orasis Investigative Site

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.